Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Abbott Labs

America First Multifamily Investors

Annaly Capital

Pfizer

For high yield hunters, market corrections are an opportunity to enhance their income stream.

Make Money In Your Sleep: 3 Big Dividends To Buy Today

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Biogen

Vertex Pharmaceuticals

There are good reasons behind analysts' optimism about these stocks.

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

Intel

Kraft Heinz

Global X Russell 2000 Covered Call ETF

Southern Company

After 32 weeks and $3,200, the Dividend Harvesting Portfolio is generating $220.29 in estimated annual income and $18.36 in monthly estimated income. In week 32, I added to my position in Southern Company and the Global X Russell 2000 Covered Call ETF.

Dividend Harvesting: Week 32 Update, $3,200 Allocated, $220.29 In Annual Dividends Yielding 6.91% With 48 Positions

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #DAYBREAK--Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study.....

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

Bristol Myers (BMY) UC Candidate Fails in Phase II Study

Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:   Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate.

Evotec Expands Neuroscience Collaboration with Bristol Myers

General Motors

Mastercard

Teva Pharmaceutical

Visa

Riding the Oracle of Omaha's coattails has long been a moneymaking strategy.

5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter

INCLUDES NEW CELL TYPES FOR STUDYING MOLECULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES TRIGGERS US$ 9.0 M PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / October 8, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its collaboration with Bristol Myers Squibb (NYSE: BMY) has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec. The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases.

Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC). The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary efficacy endpoints.

Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Colitis--Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients with Moderate to Severe Ulcerative Colitis

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

Amgen

British American Tobacco

Lockheed Martin

LyondellBasell Industries

Medical Properties Trust

Merck

Omega Healthcare Investors

Vedanta Limited

Vodafone Group

Viatris

ZIM Integrated Shipping Services

12 raises came from 49 dividend payers taking income sky high to its highest level ever. All are listed with dividend amount, yield, and other pertinent information. Portfolio value was down only 3.54%, better than most of the indexes and with income up dividend yield was 4.37%.

Rose 94 Stock Portfolio Q3/September Sky-High Dividends Update

Walgreens

Buying above-average companies at below-average prices is generally a winning strategy. I highlight 2 such blue-chip companies whose stocks have been beaten down by the market.

Not 1, But 2 Dividend Gifts From The Market

AstraZeneca

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

AT&T

Verizon

As we head into the final quarter of 2021, a handful of David Rolfe (Trades, Portfolio)'s holdings are potential buying opportunities currently.

3 David Rolfe Stocks Retreat to Near 52-Week Lows

AGNC Investment

Big-time bargains are available for opportunistic long-term investors.

3 Value Stocks That'll Make You Richer in the Fourth Quarter (and Beyond)

Bristol Myers Squibb (BMY) closed at $58.93 in the latest trading session, marking a -0.97% move from the prior day.

Bristol Myers Squibb (BMY) Stock Moves -0.97%: What You Should Know

Alibaba

Humana

With the S&P 500 up 30.65% year over year and the Buffett Indicator showing the U.S. stock market as “significantly overvalued” with an implied future return of -2.5% per year, it may feel like there are no more value opportunities left.

5 Popular Guru Stocks Trading Near 52-Week Lows

ViacomCBS

Though these companies have recorded solid financials of late, investors are overlooking them.

2 Ridiculously Cheap Growth Stocks to Buy

Short-term volatility can be a patient, long-term investor's best friend.

Bristol Myers Squibb: Should You Buy the Dip?

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Hold Investor Event on November 16

Bristol Myers Squibb to Hold Investor Event on November 16

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMA--European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination....

European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EXPLORERHCM--European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Enterprise Products Partners

Solid dividends plus strong growth? You get both with these stocks.

These 3 Dividend Stocks Could Soar Between 23% and 32%, According to Wall Street

Franklin Resources

Brookfield Infrastructure

Chevron

Flowers Foods

Gaming and Leisure Properties

Huntington Bancshares

May to August, 2021, Kiplinger-Today listed eight sets of stocks sorted as: best-buys for 2021, infrastructure-plays, value, growth, small-cap, high-yield, housing-bets, and cash-flow-gushers. Those eight "exceptional-dividend" articles revealed 86 equities,.

News for Bristol-Myers Stock (BMY)